A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy

Tomohiro Nishi, Yasuo Hamamoto, Junko Uemoto, Kei Onodera, Etsuko Warita, Yasuhiro Yamanaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Trastuzumab is the first molecular-target medicine for gastric cancer in acknowledgment of the effectiveness and safety in a randomized controlled trial for the HER2-positive gastric cancer. The HER2-positive rate of gastric cancer tends to be high for a well-differentiated adenocarcinoma. We report a case of HER2-positive scirrhous gastric carcinoma we treated, for whom a complete response was obtained by trastuzumab combination therapy. He was a 62-year-old man. In April, 2006, he was diagnosed with metastatic scirrhous gastric carcinoma (mainly poorly-differentiated adenocarcinoma). We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy. We confirmed the disappearance of the lesion at the 10 th cycle and judged it to be a complete response. The HER2 of advanced gastric cancer must be screened immediately without asking patients for their background or their clinical and pathologic features.

Original languageEnglish
Pages (from-to)2553-2555
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number13
Publication statusPublished - 2012 Jan 1

Fingerprint

Scirrhous Adenocarcinoma
Stomach Neoplasms
Stomach
Adenocarcinoma
Molecular Medicine
Therapeutics
Cisplatin
Randomized Controlled Trials
Pathology
Safety
Trastuzumab

Keywords

  • Diffuse type
  • Gastric carcinoma
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy. / Nishi, Tomohiro; Hamamoto, Yasuo; Uemoto, Junko; Onodera, Kei; Warita, Etsuko; Yamanaka, Yasuhiro.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 39, No. 13, 01.01.2012, p. 2553-2555.

Research output: Contribution to journalArticle

Nishi, Tomohiro ; Hamamoto, Yasuo ; Uemoto, Junko ; Onodera, Kei ; Warita, Etsuko ; Yamanaka, Yasuhiro. / A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy. In: Japanese Journal of Cancer and Chemotherapy. 2012 ; Vol. 39, No. 13. pp. 2553-2555.
@article{e855fad39dd8410898bccc0a7c832d13,
title = "A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy",
abstract = "Trastuzumab is the first molecular-target medicine for gastric cancer in acknowledgment of the effectiveness and safety in a randomized controlled trial for the HER2-positive gastric cancer. The HER2-positive rate of gastric cancer tends to be high for a well-differentiated adenocarcinoma. We report a case of HER2-positive scirrhous gastric carcinoma we treated, for whom a complete response was obtained by trastuzumab combination therapy. He was a 62-year-old man. In April, 2006, he was diagnosed with metastatic scirrhous gastric carcinoma (mainly poorly-differentiated adenocarcinoma). We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy. We confirmed the disappearance of the lesion at the 10 th cycle and judged it to be a complete response. The HER2 of advanced gastric cancer must be screened immediately without asking patients for their background or their clinical and pathologic features.",
keywords = "Diffuse type, Gastric carcinoma, Trastuzumab",
author = "Tomohiro Nishi and Yasuo Hamamoto and Junko Uemoto and Kei Onodera and Etsuko Warita and Yasuhiro Yamanaka",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "39",
pages = "2553--2555",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "13",

}

TY - JOUR

T1 - A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy

AU - Nishi, Tomohiro

AU - Hamamoto, Yasuo

AU - Uemoto, Junko

AU - Onodera, Kei

AU - Warita, Etsuko

AU - Yamanaka, Yasuhiro

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Trastuzumab is the first molecular-target medicine for gastric cancer in acknowledgment of the effectiveness and safety in a randomized controlled trial for the HER2-positive gastric cancer. The HER2-positive rate of gastric cancer tends to be high for a well-differentiated adenocarcinoma. We report a case of HER2-positive scirrhous gastric carcinoma we treated, for whom a complete response was obtained by trastuzumab combination therapy. He was a 62-year-old man. In April, 2006, he was diagnosed with metastatic scirrhous gastric carcinoma (mainly poorly-differentiated adenocarcinoma). We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy. We confirmed the disappearance of the lesion at the 10 th cycle and judged it to be a complete response. The HER2 of advanced gastric cancer must be screened immediately without asking patients for their background or their clinical and pathologic features.

AB - Trastuzumab is the first molecular-target medicine for gastric cancer in acknowledgment of the effectiveness and safety in a randomized controlled trial for the HER2-positive gastric cancer. The HER2-positive rate of gastric cancer tends to be high for a well-differentiated adenocarcinoma. We report a case of HER2-positive scirrhous gastric carcinoma we treated, for whom a complete response was obtained by trastuzumab combination therapy. He was a 62-year-old man. In April, 2006, he was diagnosed with metastatic scirrhous gastric carcinoma (mainly poorly-differentiated adenocarcinoma). We become clear with HER2 strong positive in a pathology tissue and started capecitabine+cisplatin+trastuzumab therapy. We confirmed the disappearance of the lesion at the 10 th cycle and judged it to be a complete response. The HER2 of advanced gastric cancer must be screened immediately without asking patients for their background or their clinical and pathologic features.

KW - Diffuse type

KW - Gastric carcinoma

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84875011031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875011031&partnerID=8YFLogxK

M3 - Article

C2 - 23235178

AN - SCOPUS:84875011031

VL - 39

SP - 2553

EP - 2555

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -